Providence Medical Technology, Inc. announced today it has obtained a CE Mark for its DTRAX Spinal System, DTRAX Cervical Cage, and DTRAX Bone Screw. This regulatory approval expands the company’s international product offering to include its entire DTRAX portfolio.
Providence has grown rapidly in the European Union and other international markets. The new CE Mark is expected to further accelerate its growth as surgeons now have more options for treating cervical degenerative disc disease.
“We are extremely pleased by the continuing regulatory recognition for our innovative products in the cervical spine market,” said Margaret Wong, Director of Regulatory Affairs at Providence. “This CE Mark also gives us a clear regulatory path for new implants and instruments within the DTRAX family in the European Union.”
“Providence launched the DTRAX Expandable Cage System in 2011,” said Jeff Smith, Chief Executive Officer of Providence. “Since then our surgeon customers have treated thousands of patients with cervical degenerative disc disease. We’re excited that our international customers now have access to this expanded DTRAX product offering.”
Providence Medical Technology is a privately held medical device company developing minimally disruptive solutions addressing the $1 billion worldwide cervical spine market. Providence is commercializing the DTRAX platform of differentiated cervical implants and instruments to treat cervical degenerative disc disease through indirect decompression and fusion.